Here's Why the Best Is Yet to Come for Novavax, Inc.
Synthetic vaccine maker Novavax (NASDAQ: NVAX) has fallen on hard times. The dramatic failure of its closely watched respiratory syncytial virus fusion (RSV F) vaccine in elderly adults last year has caused investors to reconsider whether its platform is even viable.
Novavax's stock has lost over 90% of its value in the past year, and its shares are currently bumping up against the Nasdaq's $1 minimum bid requirement. Put simply, this clinical-stage biotech is essentially on life support at this stage.
Image source: Getty Images.
Source: Fool.com
Novavax Inc. Aktie
10,77 €
-3,00 %
Einige Buy-Einschätzungen dominieren bei Novavax Inc. gegenüber Sell-Einschätzungen.
Das Community-Kursziel von 21 € für Novavax Inc. deutet auf eine deutliche Steigerung um mehr als 50% gegenüber dem aktuellen Kurs von 10.77 € hin.
